Switch to:
Also traded in: Argentina, Germany, Mexico, Sweden, Switzerland, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.25
AZN's Cash to Debt is ranked lower than
85% of the 768 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.45 vs. AZN: 0.25 )
Ranked among companies with meaningful Cash to Debt only.
AZN' s Cash to Debt Range Over the Past 10 Years
Min: 0.2  Med: 2.52 Max: N/A
Current: 0.25
Equity to Asset 0.23
AZN's Equity to Asset is ranked lower than
92% of the 707 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. AZN: 0.23 )
Ranked among companies with meaningful Equity to Asset only.
AZN' s Equity to Asset Range Over the Past 10 Years
Min: 0.23  Med: 0.44 Max: 0.59
Current: 0.23
0.23
0.59
Interest Coverage 7.92
AZN's Interest Coverage is ranked lower than
68% of the 467 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 23.06 vs. AZN: 7.92 )
Ranked among companies with meaningful Interest Coverage only.
AZN' s Interest Coverage Range Over the Past 10 Years
Min: 5.58  Med: 8.64 Max: 15.02
Current: 7.92
5.58
15.02
F-Score: 7
Z-Score: 1.51
M-Score: -2.56
WACC vs ROIC
7.15%
15.58%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 17.04
AZN's Operating margin (%) is ranked higher than
76% of the 714 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.72 vs. AZN: 17.04 )
Ranked among companies with meaningful Operating margin (%) only.
AZN' s Operating margin (%) Range Over the Past 10 Years
Min: 8.19  Med: 29.04 Max: 38.09
Current: 17.04
8.19
38.09
Net-margin (%) 11.78
AZN's Net-margin (%) is ranked higher than
69% of the 716 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.15 vs. AZN: 11.78 )
Ranked among companies with meaningful Net-margin (%) only.
AZN' s Net-margin (%) Range Over the Past 10 Years
Min: 4.73  Med: 20.91 Max: 29.72
Current: 11.78
4.73
29.72
ROE (%) 17.02
AZN's ROE (%) is ranked higher than
78% of the 744 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.16 vs. AZN: 17.02 )
Ranked among companies with meaningful ROE (%) only.
AZN' s ROE (%) Range Over the Past 10 Years
Min: 5.89  Med: 37.06 Max: 45.52
Current: 17.02
5.89
45.52
ROA (%) 5.06
AZN's ROA (%) is ranked higher than
57% of the 769 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.76 vs. AZN: 5.06 )
Ranked among companies with meaningful ROA (%) only.
AZN' s ROA (%) Range Over the Past 10 Years
Min: 2.2  Med: 14.19 Max: 20.88
Current: 5.06
2.2
20.88
ROC (Joel Greenblatt) (%) 58.30
AZN's ROC (Joel Greenblatt) (%) is ranked higher than
87% of the 762 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.16 vs. AZN: 58.30 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
AZN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 28.15  Med: 124.05 Max: 199.48
Current: 58.3
28.15
199.48
Revenue Growth (3Y)(%) -1.60
AZN's Revenue Growth (3Y)(%) is ranked lower than
71% of the 602 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. AZN: -1.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
AZN' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -42.9  Med: 1.50 Max: 19.9
Current: -1.6
-42.9
19.9
EBITDA Growth (3Y)(%) -14.90
AZN's EBITDA Growth (3Y)(%) is ranked lower than
82% of the 549 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.00 vs. AZN: -14.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
AZN' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -38.9  Med: -0.70 Max: 24.7
Current: -14.9
-38.9
24.7
EPS Growth (3Y)(%) -21.50
AZN's EPS Growth (3Y)(%) is ranked lower than
82% of the 503 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.70 vs. AZN: -21.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
AZN' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -48.9  Med: 12.90 Max: 32.1
Current: -21.5
-48.9
32.1
» AZN's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-07-30)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

AZN Guru Trades in Q2 2015

NWQ Managers 153,255 sh (+486.45%)
Murray Stahl 26,000 sh (+300.00%)
Jim Simons 3,934,600 sh (+149.47%)
Pioneer Investments 759,059 sh (+100.15%)
John Hussman 42,000 sh (+61.54%)
Manning & Napier Advisors, Inc 227,870 sh (unchged)
Steven Cohen 50,200 sh (unchged)
Francis Chou 13,000 sh (unchged)
Steven Cohen Sold Out
David Dreman Sold Out
Mario Gabelli 4,200 sh (-28.81%)
» More
Q3 2015

AZN Guru Trades in Q3 2015

Ken Fisher 27,947 sh (New)
PRIMECAP Management 183,900 sh (New)
NWQ Managers 490,535 sh (+60.04%)
Pioneer Investments 1,522,676 sh (+0.30%)
Francis Chou 26,000 sh (unchged)
Manning & Napier Advisors, Inc 455,740 sh (unchged)
Mario Gabelli Sold Out
Jim Simons 5,452,900 sh (-30.71%)
Murray Stahl 28,000 sh (-46.15%)
John Hussman 2,000 sh (-97.62%)
» More
Q4 2015

AZN Guru Trades in Q4 2015

Dodge & Cox 11,777,132 sh (New)
Ken Fisher 221,606 sh (+692.95%)
PRIMECAP Management 988,900 sh (+437.74%)
Pioneer Investments 2,201,690 sh (+44.59%)
NWQ Managers 516,215 sh (+5.24%)
Manning & Napier Advisors, Inc 459,840 sh (+0.90%)
John Hussman 2,000 sh (unchged)
Murray Stahl 28,000 sh (unchged)
Jim Simons 4,959,700 sh (-9.04%)
Francis Chou 13,000 sh (-50.00%)
» More
Q1 2016

AZN Guru Trades in Q1 2016

Jeremy Grantham 408,300 sh (New)
PRIMECAP Management 13,084,275 sh (+1223.11%)
Dodge & Cox 26,049,650 sh (+121.19%)
Jim Simons 5,682,800 sh (+14.58%)
Manning & Napier Advisors, Inc 487,770 sh (+6.07%)
Ken Fisher 233,409 sh (+5.33%)
Murray Stahl 28,302 sh (+1.08%)
John Hussman 2,000 sh (unchged)
Francis Chou 13,000 sh (unchged)
NWQ Managers 506,785 sh (-1.83%)
Pioneer Investments 446,513 sh (-79.72%)
» More
» Details

Insider Trades

Latest Guru Trades with AZN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:XTER:BAYA, NYSE:LLY, TSE:4503, TSE:4528, TSE:4578 » details
Traded in other countries:AZN.Argentina, ZEG.Germany, AZNN.Mexico, AZN.Sweden, OXAZN.Switzerland, AZN.UK, AZNCF.USA,
AstraZeneca PLC is a biopharmaceutical company. It is engaged in the discovery and development of new products, which are then manufactured, marketed and sold.

AstraZeneca PLC was incorporated in England and Wales on June 17, 1992. From February 1993 until April 1999, the Company was called Zeneca Group PLC. On 6 April 1999, the Company changed its name to AstraZeneca PLC. It is a biopharmaceutical company. The Company is engaged in the discovery and development of new products, which are then manufactured, marketed and sold. It is engaged in healthcare: Cardiovascular and Metabolic disease (CVMD); Oncology; and Respiratory, Inflammation and Autoimmunity (RIA). The Company is also engaged in the Infection, Neuroscience and Gastrointestinal (ING) disease areas. It operates in more than 100 countries.

Ratios

vs
industry
vs
history
P/E(ttm) 25.41
AZN's P/E(ttm) is ranked higher than
54% of the 558 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.44 vs. AZN: 25.41 )
Ranked among companies with meaningful P/E(ttm) only.
AZN' s P/E(ttm) Range Over the Past 10 Years
Min: 6.04  Med: 12.35 Max: 99.47
Current: 25.41
6.04
99.47
Forward P/E 13.68
AZN's Forward P/E is ranked higher than
51% of the 90 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.95 vs. AZN: 13.68 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 25.24
AZN's PE(NRI) is ranked higher than
54% of the 549 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.81 vs. AZN: 25.24 )
Ranked among companies with meaningful PE(NRI) only.
AZN' s PE(NRI) Range Over the Past 10 Years
Min: 6.02  Med: 12.35 Max: 99.72
Current: 25.24
6.02
99.72
Price/Owner Earnings (ttm) 19.86
AZN's Price/Owner Earnings (ttm) is ranked higher than
71% of the 265 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.19 vs. AZN: 19.86 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
AZN' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 5.38  Med: 11.63 Max: 28.08
Current: 19.86
5.38
28.08
P/B 4.76
AZN's P/B is ranked lower than
74% of the 762 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.80 vs. AZN: 4.76 )
Ranked among companies with meaningful P/B only.
AZN' s P/B Range Over the Past 10 Years
Min: 2.3  Med: 3.82 Max: 6.97
Current: 4.76
2.3
6.97
P/S 3.00
AZN's P/S is ranked lower than
53% of the 714 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.76 vs. AZN: 3.00 )
Ranked among companies with meaningful P/S only.
AZN' s P/S Range Over the Past 10 Years
Min: 1.61  Med: 2.41 Max: 3.92
Current: 3
1.61
3.92
PFCF 28.68
AZN's PFCF is ranked lower than
52% of the 199 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 26.71 vs. AZN: 28.68 )
Ranked among companies with meaningful PFCF only.
AZN' s PFCF Range Over the Past 10 Years
Min: 6.18  Med: 13.48 Max: 179.65
Current: 28.68
6.18
179.65
POCF 16.13
AZN's POCF is ranked higher than
57% of the 265 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.71 vs. AZN: 16.13 )
Ranked among companies with meaningful POCF only.
AZN' s POCF Range Over the Past 10 Years
Min: 5.35  Med: 8.69 Max: 26.98
Current: 16.13
5.35
26.98
EV-to-EBIT 24.33
AZN's EV-to-EBIT is ranked lower than
59% of the 537 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.64 vs. AZN: 24.33 )
Ranked among companies with meaningful EV-to-EBIT only.
AZN' s EV-to-EBIT Range Over the Past 10 Years
Min: 4.3  Med: 8.60 Max: 61
Current: 24.33
4.3
61
EV-to-EBITDA 14.29
AZN's EV-to-EBITDA is ranked higher than
60% of the 569 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.81 vs. AZN: 14.29 )
Ranked among companies with meaningful EV-to-EBITDA only.
AZN' s EV-to-EBITDA Range Over the Past 10 Years
Min: 3.6  Med: 6.80 Max: 20.5
Current: 14.29
3.6
20.5
Shiller P/E 14.91
AZN's Shiller P/E is ranked higher than
89% of the 146 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 46.77 vs. AZN: 14.91 )
Ranked among companies with meaningful Shiller P/E only.
AZN' s Shiller P/E Range Over the Past 10 Years
Min: 10.05  Med: 15.59 Max: 26.75
Current: 14.91
10.05
26.75
Current Ratio 0.80
AZN's Current Ratio is ranked lower than
94% of the 662 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.40 vs. AZN: 0.80 )
Ranked among companies with meaningful Current Ratio only.
AZN' s Current Ratio Range Over the Past 10 Years
Min: 0.64  Med: 1.49 Max: 2.03
Current: 0.8
0.64
2.03
Quick Ratio 0.65
AZN's Quick Ratio is ranked lower than
91% of the 662 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.87 vs. AZN: 0.65 )
Ranked among companies with meaningful Quick Ratio only.
AZN' s Quick Ratio Range Over the Past 10 Years
Min: 0.54  Med: 1.26 Max: 2.03
Current: 0.65
0.54
2.03
Days Inventory 181.10
AZN's Days Inventory is ranked lower than
78% of the 668 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 114.30 vs. AZN: 181.10 )
Ranked among companies with meaningful Days Inventory only.
AZN' s Days Inventory Range Over the Past 10 Years
Min: 88.45  Med: 122.07 Max: 157.83
Current: 181.1
88.45
157.83
Days Sales Outstanding 98.16
AZN's Days Sales Outstanding is ranked lower than
66% of the 620 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 74.15 vs. AZN: 98.16 )
Ranked among companies with meaningful Days Sales Outstanding only.
AZN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 59.12  Med: 68.49 Max: 95.12
Current: 98.16
59.12
95.12
Days Payable 307.34
AZN's Days Payable is ranked higher than
95% of the 589 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 71.47 vs. AZN: 307.34 )
Ranked among companies with meaningful Days Payable only.
AZN' s Days Payable Range Over the Past 10 Years
Min: 147.39  Med: 213.74 Max: 543.62
Current: 307.34
147.39
543.62

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 4.86
AZN's Dividend Yield is ranked higher than
93% of the 585 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.50 vs. AZN: 4.86 )
Ranked among companies with meaningful Dividend Yield only.
AZN' s Dividend Yield Range Over the Past 10 Years
Min: 1.94  Med: 4.55 Max: 7.64
Current: 4.86
1.94
7.64
Dividend Payout 1.21
AZN's Dividend Payout is ranked lower than
92% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.33 vs. AZN: 1.21 )
Ranked among companies with meaningful Dividend Payout only.
AZN' s Dividend Payout Range Over the Past 10 Years
Min: 0.23  Med: 0.93 Max: 4.87
Current: 1.21
0.23
4.87
Dividend Growth (3y) -1.80
AZN's Dividend Growth (3y) is ranked lower than
66% of the 283 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.70 vs. AZN: -1.80 )
Ranked among companies with meaningful Dividend Growth (3y) only.
AZN' s Dividend Growth (3y) Range Over the Past 10 Years
Min: -4.5  Med: 11.10 Max: 28.3
Current: -1.8
-4.5
28.3
Forward Dividend Yield 6.62
AZN's Forward Dividend Yield is ranked higher than
96% of the 568 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.62 vs. AZN: 6.62 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 5.39
AZN's Yield on cost (5-Year) is ranked higher than
87% of the 709 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.95 vs. AZN: 5.39 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
AZN' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 2.15  Med: 5.05 Max: 8.48
Current: 5.39
2.15
8.48
3-Year Average Share Buyback Ratio -0.50
AZN's 3-Year Average Share Buyback Ratio is ranked higher than
73% of the 425 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.40 vs. AZN: -0.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
AZN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -23.3  Med: 1.80 Max: 4.9
Current: -0.5
-23.3
4.9

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.35
AZN's Price/Projected FCF is ranked higher than
75% of the 311 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.53 vs. AZN: 1.35 )
Ranked among companies with meaningful Price/Projected FCF only.
AZN' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.49  Med: 1.29 Max: 5.98
Current: 1.35
0.49
5.98
Price/Median PS Value 1.24
AZN's Price/Median PS Value is ranked lower than
60% of the 680 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.09 vs. AZN: 1.24 )
Ranked among companies with meaningful Price/Median PS Value only.
AZN' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.39  Med: 1.16 Max: 2.47
Current: 1.24
0.39
2.47
Earnings Yield (Greenblatt) (%) 4.09
AZN's Earnings Yield (Greenblatt) (%) is ranked higher than
59% of the 782 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.00 vs. AZN: 4.09 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
AZN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1.6  Med: 11.70 Max: 23.1
Current: 4.09
1.6
23.1
Forward Rate of Return (Yacktman) (%) -15.21
AZN's Forward Rate of Return (Yacktman) (%) is ranked lower than
87% of the 323 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.36 vs. AZN: -15.21 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
AZN' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -17.3  Med: 18.40 Max: 27.5
Current: -15.21
-17.3
27.5

More Statistics

Revenue (TTM) (Mil) $24,766
EPS (TTM) $ 1.15
Beta0.75
Short Percentage of Float0.76%
52-Week Range $27.68 - 34.94
Shares Outstanding (Mil)2,530.00

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 23,789 23,842 26,557
EPS($) 1.88 2.08 2.52
EPS without NRI($) 1.88 2.08 2.52
» More Articles for NYSE:AZN

Headlines

Articles On GuruFocus.com
Dividend and Value Opportunities in the Large-Cap Pharmaceutical Space Apr 05 2016 
Francis Chou Raises Stake in Resolute Forest Products Mar 20 2016 
Signature Select Canadian Fund Second Quarter 2015 Market Commentary Sep 22 2015 
Francis Chou Doubles Stake in AstraZeneca Aug 11 2015 
Last Month Insiders Bought Over $300 Million Of This Biotech Jun 26 2015 
Guru Stocks at 52-Week Lows: XOM, WMT, CVX, AZN, COP Jun 21 2015 
Amgen And AstraZeneca’s Deal On Psoriasis Drug Faces Termination May 27 2015 
Johnson & Johnson A Good Investment Despite Current Lows May 14 2015 
Vanguard Adds to Four of Its Largest Stakes May 04 2015 
HealthCare Stocks That Can Make Investors Healthier Apr 08 2015 

More From Other Websites
Rlypsa Stock Pops on New Data and a Huge Risk May 23 2016
Are AstraZeneca plc, Eco Animal Health Group plc and Advanced Medical Solutions Group plc the top... May 23 2016
[$$] China Drug Deal Will Slash Prices of Three Top-Selling Treatments May 20 2016
[$$] China Drug Deal Will Slash Prices of Top Treatments May 20 2016
China slashes GSK, AstraZeneca drug prices in cost-cutting drive May 20 2016
8 Stocks on the Move After ASCO Cancer Abstracts May 19 2016
AstraZeneca Highlights Continued Progress of Oncology Pipeline at ASCO 2016 Leadership in DNA Damage... May 19 2016
AstraZeneca plc goes ‘nuclear’ on R&D spend to double sales May 19 2016
Europe close: Banks lead gains May 18 2016
FTSE 100 slips as Burberry earnings, U.S. rate-hike prospects weigh May 18 2016
AstraZeneca's Severe Asthma Drug Positive in Phase III May 18 2016
4 Stunning 5%+ Yielders! AstraZeneca plc, TUI AG, Marston’s plc and Taylor Wimpey plc May 18 2016
FTSE 100 flops as Burberry earnings, U.S. rate-hike prospects weigh May 18 2016
Why is Neil Woodford so bullish on drugmakers GlaxoSmithKline plc, AstraZeneca plc and 4D Pharma... May 18 2016
Europe open: Stocks nudge lower amid US rate hike concerns May 18 2016
Insight - Pascal Soriot's big experiment: reinventing AstraZeneca May 18 2016
Pascal Soriot's big experiment: reinventing AstraZeneca May 18 2016
Pascal Soriot's big experiment: reinventing AstraZeneca May 18 2016
AstraZeneca's Lynparza fails in gastric cancer combination test May 18 2016
AstraZeneca's Lynparza fails in gastric cancer combination test May 18 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)